Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.
Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.
复制标题
DOI：
10.1038/s41523-021-00290-0
复制
发表时间：
2021-07-02
影响因子：
5.9
通讯作者：
Chilkoti A
中科院分区：
文献类型：
--
作者：
Joh DY;Heggestad JT;Zhang S;Anderson GR;Bhattacharyya J;Wardell SE;Wall SA;Cheng AB;Albarghouthi F;Liu J;Oshima S;Hucknall AM;Hyslop T;Hall AHS;Wood KC;Shelley Hwang E;Strickland KC;Wei Q;Chilkoti A
在资源有限的环境中，乳腺癌的管理受到缺乏低成本，后勤可持续的方法对分子和细胞诊断病理学服务，需要指导治疗的阻碍。为了解决这些局限性，我们开发了一种基于多模式手机的平台EpiView-D4，可以在1小时内直接从乳腺组织标本的细针穿刺（FNA）中评估细胞形态和临床相关生物标志物的分子表达。EpiView-D4由两个组件组成：（1）构建在“无污染”聚合物刷涂层（“D4”）上的免疫诊断芯片，其直接从粗细胞裂解物定量蛋白质生物标志物的表达，以及（2）定制的基于手机的光学显微镜（“EpiView”），其设计用于成像细胞学制备和D4测定读数。作为概念验证，我们使用EpiView-D4评估人表皮生长因子受体-2（HER 2）表达，并使用癌细胞系、动物模型和人体组织标本验证性能。我们发现，通过EpiView-D4成像的FNA细胞学标本（使用快速染色试剂盒在不到5分钟内制备）足以评估病变细胞结构和肿瘤内容物。我们还发现我们的设备可以可靠地区分多种不同细胞系和动物异种移植物中的HER 2表达水平。在一项人体组织的初步研究中（n = 19），我们能够准确地对FNA标本中的HER 2阴性和HER 2阳性肿瘤进行分类。综上所述，EpiView-D4提供了一个有前途的替代侵入性和往往无法获得的病理服务，并可能使民主化的有效乳腺癌管理在有限的资源设置。
Management of breast cancer in limited-resource settings is hindered by a lack of low-cost, logistically sustainable approaches toward molecular and cellular diagnostic pathology services that are needed to guide therapy. To address these limitations, we have developed a multimodal cellphone-based platform—the EpiView-D4—that can evaluate both cellular morphology and molecular expression of clinically relevant biomarkers directly from fine-needle aspiration (FNA) of breast tissue specimens within 1 h. The EpiView-D4 is comprised of two components: (1) an immunodiagnostic chip built upon a “non-fouling” polymer brush-coating (the “D4”) which quantifies expression of protein biomarkers directly from crude cell lysates, and (2) a custom cellphone-based optical microscope (“EpiView”) designed for imaging cytology preparations and D4 assay readout. As a proof-of-concept, we used the EpiView-D4 for assessment of human epidermal growth factor receptor-2 (HER2) expression and validated the performance using cancer cell lines, animal models, and human tissue specimens. We found that FNA cytology specimens (prepared in less than 5 min with rapid staining kits) imaged by the EpiView-D4 were adequate for assessment of lesional cellularity and tumor content. We also found our device could reliably distinguish between HER2 expression levels across multiple different cell lines and animal xenografts. In a pilot study with human tissue (n = 19), we were able to accurately categorize HER2-negative and HER2-positve tumors from FNA specimens. Taken together, the EpiView-D4 offers a promising alternative to invasive—and often unavailable—pathology services and may enable the democratization of effective breast cancer management in limited-resource settings.
登录
查看更多内容
影响因子：
158.5
作者：
Joensuu, H;Kellokumpu-Lehtinen, P;Isola, J
通讯作者：
Isola, J
影响因子：
45.3
作者：
Cobleigh, MA;Vogel, CL;Slamon, DJ
通讯作者：
Slamon, DJ
影响因子：
2.1
作者：
Hucknall, Angus;Simnick, Andrew J.;Ratner, Buddy D.
通讯作者：
Ratner, Buddy D.
影响因子：
6.2
作者：
Hendrick, R. Edward;Baker, Jay A.;Helvie, Mark A.
通讯作者：
Helvie, Mark A.
影响因子：
16.6
作者：
Chung, Inhee;Reichelt, Mike;Shao, Lily;Akita, Robert W.;Koeppen, Hartmut;Rangell, Linda;Schaefer, Gabriele;Mellman, Ira;Sliwkowski, Mark X.
通讯作者：
Sliwkowski, Mark X.